Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma.
CCA
FDA
biliary
cancer
cholangiocarcinoma
targeted therapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 May 2022
26 May 2022
Historique:
received:
18
04
2022
revised:
19
05
2022
accepted:
24
05
2022
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
11
6
2022
Statut:
epublish
Résumé
Cholangiocarcinoma (CCA) represents approximately 3% of gastrointestinal malignancies worldwide and constitutes around 10-15% of all primary liver cancers, being only second to hepatocellular carcinoma. Mortality from CCA has been on the rise in recent decades, and in the United States alone there has been a 36% increase in CCA from 1999 to 2014, with over 7000 CCA mortalities since 2013. Targeted therapies, which have been gaining interest due to their greater specificity toward cancer cells, have only recently started gaining FDA approval for the treatment of CCA. In this manuscript, we will go through the timeline of current FDA-approved targeted therapies as well as those that have gained FDA breakthrough therapy designation.
Identifiants
pubmed: 35681621
pii: cancers14112641
doi: 10.3390/cancers14112641
pmc: PMC9179455
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Mol Clin Oncol. 2021 Aug;15(2):152
pubmed: 34141431
Transl Lung Cancer Res. 2020 Feb;9(1):111-138
pubmed: 32206559
Trop Geogr Med. 1980 Jun;32(2):95-100
pubmed: 6252671
Cancers (Basel). 2022 Mar 30;14(7):
pubmed: 35406533
Nat Biotechnol. 2005 Sep;23(9):1147-57
pubmed: 16151408
Visc Med. 2021 Feb;37(1):18-25
pubmed: 33708815
Chin Med J (Engl). 2021 Dec 22;135(3):261-267
pubmed: 34935688
Lancet Oncol. 2020 Jun;21(6):796-807
pubmed: 32416072
Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261-80
pubmed: 27095655
Cancer. 2015 Sep 15;121(18):3290-7
pubmed: 26052689
Onco Targets Ther. 2021 Jul 13;14:4149-4162
pubmed: 34285507
PLoS One. 2020 Apr 21;15(4):e0231877
pubmed: 32315352
Cancers (Basel). 2022 Jan 31;14(3):
pubmed: 35159010
J Clin Oncol. 2018 Jan 20;36(3):276-282
pubmed: 29182496
JAMA Oncol. 2015 Jul;1(4):505-27
pubmed: 26181261
Front Pharmacol. 2021 Dec 16;12:795381
pubmed: 34975492
J Gastrointest Oncol. 2014 Dec;5(6):408-13
pubmed: 25436118
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588
pubmed: 32606456
Immunotherapy. 2021 Sep;13(13):1113-1134
pubmed: 34190581
Cancer. 2021 Apr 15;127(8):1266-1274
pubmed: 33320344
BMC Gastroenterol. 2016 Sep 21;16(1):117
pubmed: 27655244
Curr Gastroenterol Rep. 2017 Jan;19(1):2
pubmed: 28110453
Am Fam Physician. 2008 Feb 1;77(3):311-9
pubmed: 18297955
Infect Dis Poverty. 2012 Oct 25;1(1):4
pubmed: 23849183
Gastroenterology. 2013 Apr;144(4):829-40
pubmed: 23295441
Ann Oncol. 2016 Apr;27(4):599-608
pubmed: 27005468
Ann Oncol. 2005;16 Suppl 2:ii93-6
pubmed: 15958484
JAMA Oncol. 2021 Nov 01;7(11):1669-1677
pubmed: 34554208
Nature. 2009 Dec 10;462(7274):739-44
pubmed: 19935646
Radiat Oncol. 2020 Jan 15;15(1):15
pubmed: 31941520
Future Oncol. 2020 Oct;16(30):2385-2399
pubmed: 32677452
J Gastrointest Cancer. 2022 Jan 13;:
pubmed: 35023010
Curr Oncol. 2022 May 17;29(5):3585-3594
pubmed: 35621680
Lancet Oncol. 2020 May;21(5):671-684
pubmed: 32203698
J Hepatobiliary Pancreat Sci. 2014 May;21(5):301-8
pubmed: 24408775
Cancer Cell. 2010 Dec 14;18(6):553-67
pubmed: 21130701
Blood. 2015 Jan 8;125(2):296-303
pubmed: 25398940
Ann Oncol. 2001;12 Suppl 1:S3-8
pubmed: 11521719
Front Oncol. 2015 Aug 10;5:183
pubmed: 26322273
Ann Surg Oncol. 2022 Mar 16;:
pubmed: 35294656
Cancer Cell. 2018 Aug 13;34(2):186-195
pubmed: 29805076
J Transl Med. 2016 Oct 13;14(1):292
pubmed: 27737711
Mol Biol Int. 2014;2014:852748
pubmed: 25276427
Eur J Gastroenterol Hepatol. 2022 Mar 1;34(3):338-344
pubmed: 34775457
Cells. 2019 Jun 18;8(6):
pubmed: 31216761
JCO Precis Oncol. 2018 Nov;2:1-12
pubmed: 35135097
Nature. 2012 Feb 15;483(7390):479-83
pubmed: 22343889
Cancer Treat Res Commun. 2021;27:100351
pubmed: 33752169
N Engl J Med. 2009 Sep 10;361(11):1058-66
pubmed: 19657110
Medicina (Kaunas). 2019 Feb 08;55(2):
pubmed: 30743998
Br J Cancer. 2019 Jan;120(2):165-171
pubmed: 30420614
Biosci Trends. 2020 Nov 4;14(5):328-341
pubmed: 32830166
Cancers (Basel). 2021 Sep 29;13(19):
pubmed: 34638395
Br J Cancer. 2016 Feb 16;114(4):362-7
pubmed: 26742008
Oncol Lett. 2020 Dec;20(6):381
pubmed: 33154779
Ann Oncol. 2014 Dec;25(12):2328-2338
pubmed: 24769639
Nutr Cancer. 2022;74(5):1724-1733
pubmed: 34323130
Cancers (Basel). 2020 Mar 20;12(3):
pubmed: 32244867
Nat Rev Gastroenterol Hepatol. 2011 Aug 02;8(9):512-22
pubmed: 21808282
PLoS One. 2022 Jan 27;17(1):e0262589
pubmed: 35085313
Surgery. 2022 Apr;171(4):859-866
pubmed: 35123795
Science. 2013 May 3;340(6132):622-6
pubmed: 23558173
Cytokine Growth Factor Rev. 2005 Apr;16(2):139-49
pubmed: 15863030
Nat Rev Cancer. 2010 Feb;10(2):116-29
pubmed: 20094046
Dig Surg. 2008;25(2):126-32
pubmed: 18446034
J Hepatol. 2022 May;76(5):1109-1121
pubmed: 35167909
Nat Rev Dis Primers. 2021 Sep 9;7(1):65
pubmed: 34504109
Clin Cancer Res. 2016 Jan 1;22(1):259-67
pubmed: 26373574
J Gastroenterol. 2022 May;57(5):387-395
pubmed: 35357571
Future Oncol. 2020 Oct;16(30):2375-2384
pubmed: 32580579
Cancer Biol Ther. 2005 Jan;4(1):6-13
pubmed: 15684606
Lancet Gastroenterol Hepatol. 2021 Oct;6(10):803-815
pubmed: 34358484
J Hepatol. 2019 Jul;71(1):104-114
pubmed: 30910538
J Carcinog. 2015 Feb 23;14:1
pubmed: 25788866
Nature. 2012 Feb 15;483(7390):474-8
pubmed: 22343901
Cancer Treat Rev. 2021 Apr;95:102170
pubmed: 33735689
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404